The disclosure relates to methods and compositions for reducing memory loss. Specifically, methods of using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimers disease (AD) are provided. Further provided are methods for identifying a mammal as having AD by detecting the presence of an elevated level of gamma-aminobutyric acid (GABA) within a mammals brain.
